Curative treatment for severe sickle cell disease: allogeneic transplantation. Clin Adv Hematol Oncol 2015 Apr;13(4):249-56
Date
09/10/2015Pubmed ID
26352583Scopus ID
2-s2.0-84926621177 (requires institutional sign-in at Scopus site) 5 CitationsAbstract
Sickle cell disease is an inherited hematologic disorder that in its severe form can result in substantial morbidity and early mortality. Patients with this disorder can suffer from severe pain, lung disease, and strokes, resulting in chronic debilitating conditions, end organ dysfunction, and organ failure. The health care costs of caring for these chronically ill patients are substantial. Allogeneic transplantation is a modality that has the potential to cure these patients. To date, matched sibling donor transplantation is widely accepted as a standard of care for pediatric patients. Utilizing alternative donors for transplant is still under investigation, as is transplant for adult patients with sickle cell disease. This review focuses on the most recent data for hematopoietic cell transplantation for patients with sickle cell disease.
Author List
Oshrine B, Talano JAAuthor
Julie-An M. Talano MD Professor in the Pediatrics department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Anemia, Sickle CellCord Blood Stem Cell Transplantation
Haplotypes
Hematopoietic Stem Cell Transplantation
Histocompatibility Testing
Humans
Siblings
Tissue Donors
Transplantation Conditioning
Transplantation, Homologous
